Royalty Report: Drugs, Therapeutic, Biotechnology – Collection: 26641


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Therapeutic
  • Biotechnology
  • Cancer
  • Delivery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26641

License Grant
The Canadian Licensor announced the signing of a Memorandum of Understanding  with the Licensee from Tunisia.
License Property
This binding MOU aims at working jointly at the development and the production of several therapeutic proteins.  The alliance, or memorandum of understanding covers a 10-year period and the marketing of erythropoietin, interferon beta and growth factors such as G-CSF to Indonesia, Pakistan and countries in Africa, the Middle East and in Europe.

The first proteins should reach those markets in 2009 to treat diseases such as cancer and multiple sclerosis.  The deal means Tunisia will be home to the first manufacturing facility for therapeutic proteins in that part of the world.

IPSCIO Record ID: 26640

License Grant
Japanese Licensor hereby grants an exclusive licence to Canadian Licensee to market and produce the Products.
License Property
The Products shall comprise, but not be limited to, the following
·Recombinant Human Interferon alpha-2a (rHulFN-a 2a) and alpha-2b (rHulFN-a 2b)
·Recombinant Human granulocyte colony stimulating factor (rHuG-CSF);
·Recombinant Human granulocyte macrophage colony stimulating factor (rHuGM-CSF);
·Interleukin 2
·EPO (erythropoietin)

The Company has acquired license to patented technologies related to the production of therapeutic proteins, alpha and beta interferon, Interleukin 2, EPO (erythropoietin) and human growth factors (rHuG-CSF and rHuGM-CSF).

Field of Use
Field of Use relates to the medical industry.

IPSCIO Record ID: 25837

License Grant
The Canadian Corporation announced today the signing of a European licensing agreement for the development and commercialization of NX-1207, licensor's (Canadian) Phase III investigational drug currently in clinical development in the U.S. for the treatment of benign prostatic hyperplasia (BPH).
License Property
Under the terms of the agreement, licensee (Italian) receives exclusive rights to develop and subsequently market and sell NX-1207 in Europe including Russia and the CIS, the Middle East, the Maghreb area of North Africa and South Africa (i.e. a total of 81 countries).

NX-1207 is an office-based pro-apoptotic protein injectable for BPH and for low grade localized prostate cancer. The drug mechanism of action is to lead to programmed natural cell death (apoptosis) selectively in prostate glands when injected intraprostatically by the transrectal route.

Field of Use
The licensing agreement covers the use of NX-1207 for the treatment of BPH as the initial indication for development and commercialization.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.